PMDA drug package insert
ブセレリン点鼻液0.15%「F」
PMDA Prescription drug · 富士製薬工業株式会社 · package insert Dec 28, 2022
Key facts
| Brand names | ブセレリン点鼻液0.15%「F」 |
|---|---|
| Nonproprietary names | ブセレリン酢酸塩 |
| Companies | 製造販売元／富士製薬工業株式会社 |
| Product type | Prescription drug |
| Therapeutic category | GnRH誘導体製剤 |
| Therapeutic category codes | 872499 |
| YJ codes | 2499701R1095 |
| Approval numbers | 30100AMX00060 |
| Package insert edition | 第2版 |
| Package insert date | Dec 28, 2022 |
| PMDA document key | 670109_2499701R1095_1 |
| PMDA company code | 670109 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: